The present invention relates to methods and systems for predicting the likelihood of acute respiratory distress syndrome (ARDS) in adult subjects. The invention further relates to methods of treatment and identification of subjects with an increased likelihood of developing ARDS as determined by the disclosed methods.

The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

Provided herein are compositions, systems, kits, and methods for detecting cardiovascular disease, risk of cardiovascular disease, and/or reverse cholesterol transport potential in a subject based on the levels of PIP2 phospholipid in the subject.

The object of the present invention is to provide an easy and quick detection method for detecting an oxLDL/β.sub.2GPI complex in biological samples, and a detection kit therefor. The present invention attains this object by providing a detection method for detecting an oxLDL/β.sub.2GPI complex, which uses a test strip for lateral flow assay, comprising a step of capturing the oxLDL/β.sub.2GPI complex in the test sample in a predetermined position on the test strip by a first binding component that binds to the oxLDL/β.sub.2GPI complex; and a step of labeling the oxLDL/β.sub.2GPI complex captured in the predetermined position on the test strip by making a second binding component comprising a labeling agent be bound to the captured oxLDL/β.sub.2GPI complex, and a detection kit therefor.

Described herein are methods for stratifying Alzheimer's disease among male and female subjects by analyzing biomarker metabolites. In one aspect, the biomarker metabolite comprises one or more of PC ae C44:4, PC ac C44:5, or PA ae C44:6; or PC ac C44:4, PC ac C44:5, PC aa C32:1, PC aa C32:0, or PC ae C42:4.

Provided herein are methods of detecting lipids in humans suspected of having cancer, in particular detecting lipids in samples from a human suspected of having breast or lung cancer.

The present disclosure relates to an extracellular vesicle purification material and purification method. The purification method adopts metal oxide microspheres or magnetic beads that can reversibly bind to phosphatidylserine to purify extracellular vesicles, and the purification material comprises nano zirconium dioxide microspheres, nano titanium dioxide microspheres or nano aluminum oxide microspheres, nano zirconium dioxide magnetic microspheres, nano titanium dioxide magnetic microspheres or nano aluminum oxide magnetic microspheres, and porous zirconium dioxide nano microspheres, porous titanium dioxide nano microspheres or porous aluminum oxide nano microspheres. The purification method of the present disclosure can quickly purify multiple samples: serum/plasma, urine and cell culture supernatant, has a moderate flux so as to retain extracellular vesicles to the greatest extent, and can obtain high-purity extracellular vesicles, without chelating agents and other reagents that may affect subsequent experiments, via elution.

Provided herein are compositions of trehalose phospholipids and uses thereof, e.g., compounds and compositions comprising 6,6′-diphosphatidyltrehalose (diPT) and analogs thereof with modifications of the diPT chemical scaffold, that bind and agonize Mincle, and the use thereof as adjuvants.

The present invention is directed to a method for determining a subject is afflicted with or having increased risk of developing an alpha-synuclein-associated disease or disorder, Parkinson's disease, or both. The method further includes administering to the subject determined as being afflicted with or having increased risk of developing an alpha-synuclein-associated disease or disorder a therapeutically effective amount of an agent characterized by being capable of decreasing signaling transduced by a member of PI4,5P.sub.2 PI3,4P.sub.2, PI3,5P2, PI3,4,5P.sub.3, PI3P, PI4P signal transduction pathway.

A rapid detection method of a target biomolecule comprising an antigenic moiety is provided. The method includes providing a source biological sample comprising the target biomolecule; contacting the source biological sample to an ion-exchange medium; eluting the captured-target biomolecule from the ion-exchange medium as an eluate, and loading the eluate to a rapid diagnostic testing device comprising an antibody. The eluate comprises a concentrated form of the biomolecule in a solution having a salt concentration greater than 150 mM. A concentration of the target biomolecule in the eluate is in a range from about 2× to 25× compared to a concentration of the biomolecule in the source biological sample. The target biomolecule binds to the antibody under the salt concentration of greater than 150 mM. A device for rapid detection of target biomolecule is also provided.